Скачать или смотреть Therapy to prevent hepatocellular carcinoma in people with liver cirrhosis

THERAPY TO PREVENT HEPATOCELLULAR CARCINOMA IN PEOPLE WITH LIVER CIRRHOSIS

Professor John Olynyk, Liver Specialist, Gastroenterologist & Hepatologist,
Fiona Stanley and Fremantle Hospitals
South Metropolitan Health Service, Western Australia &

Associate Director, Clinical Engagement,
Curtin Medical Research Institute, Curtin University, Western Australia

RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026

Professor John Olynyk is a Gastroenterologist & Hepatologist with over 30 years' experience, primarily at The Fiona Stanley & Fremantle Hospital Group. He planned the Gastroenterology and Hepatology Service for the Fiona Stanley Hospital and was Head Department from 2010 until 2020.

Professor John Olynyk was appointed as Associate Dean and Head of the Medical Discipline at Curtin University in 2023 until 2025 and is now Associate Director, Clinical Engagement, Curtin Medical Research Institute, Curtin University.

Professor John Olynyk has a long and productive history of research in the field of haemochromatosis, liver disease and iron metabolism. He has sustained 27 years of continuous funding from the NHMRC and published over 270 peer reviewed publications with nearly 20,000 citations. He is patron of Haemochromatosis Australia and currently serves on the Royal Australasian College of Physicians overseas trained physicians assessment panel.

He has been a member of multiple national and international professional organisations. He was a keynote speaker at the UK Liver Cancer Meeting at Cambridge University in 2024. Currently he is leading a multicentre, international NHMRC-funded clinical trial examining whether aspirin therapy can prevent hepatocellular carcinoma in people with cirrhosis.

Source: Supplied

SEE OTHER RESEARCHER PROFILES
Bench Side Story
www.benchsidestory.com

Get your own interviews and research published on Bench Side Story
https://benchsidestory.com/contact/